SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is experiencing an explosive price surge, driven by increasing physical demand, significant industrial use in new technologies like AI and solar, and looming export restrictions from China. This rally is sparking intense debate within the community, with many bullish investors seeing it as a long-awaited re-pricing after years of perceived suppression, while a vocal contingent warns of an overextended "bubble" or "blow-off top" anticipating a sharp correction.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is currently experiencing extreme volatility and frequent trading halts, fueling a heated debate among investors. Bulls are driving a potential short squeeze, pointing to its low float and high borrow rates, while bears caution against a pump-and-dump, often referencing its nature as a Chinese SPAC. The community is actively discussing whether this momentum will lead to further parabolic gains or a rapid reversal, drawing parallels to other recent volatile low-float plays.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid China's recent sanctions, a move widely interpreted by the community as validation of its strategic importance and a bullish signal for a U.S. defense contractor. This, alongside the impending U.S. ban on foreign-made drones and significant anticipated defense spending, is fueling community discussion around RCAT's readiness for substantial government contracts and market share expansion.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to anticipation for its CES 2026 showcase of the AI-powered Athena platform and the continued integration of its Marigold acquisition. The community widely regards the stock as a deeply undervalued leader in AI-driven marketing technology, expecting a significant re-rating as the company progresses towards durable cash generation. Despite persistent discussions about market manipulation and a past lawsuit, strong institutional interest and consistent financial performance are fueling bullish conviction for a major breakout.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending due to its specialized AI chips, particularly the energy-efficient Gemini-II APU, which is gaining traction for edge computing in defense and drone applications. The stock is a focal point of intense community debate, with bulls highlighting recent academic validation and potential government contracts as key catalysts, while bears point to commercial struggles and fundamental technology concerns, fueling significant market volatility.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares is trending as gold prices surge to new all-time highs, propelled by ongoing geopolitical tensions, a weakening dollar, and growing expectations for future Fed rate cuts. The community is actively debating gold's role as a safe-haven asset amid global economic uncertainty and central bank de-dollarization, with some anticipating further upside while others caution about a potential pullback after its rapid ascent.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals (UPC) is trending sharply due to its extremely low float, fueling speculation of a massive short squeeze and rapid price movements including trading halts. The community is actively debating its potential for significant upside, with some highlighting its strong cash position, while others warn of a pump-and-dump in the volatile small-cap 'China floater' sector. This polarized sentiment is driving intense conversation around its dramatic market activity.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending amid an explosive global surge in silver prices, significantly higher in Asian markets, driven by severe supply deficits and robust industrial demand. Despite widespread frustration among investors over AG's stock lagging the metal's performance, the community firmly anticipates an inevitable, substantial catch-up rally for this pure-play silver miner.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Trust - ProShares Ultra Silver

ProShares Ultra Silver ($AGQ) is trending as the community debates a historic 'silver squeeze,' driven by surging physical demand and anticipation of future Chinese export restrictions. Investors are keenly watching silver's potential to play catch-up to gold's historical ratio, with many expecting substantial price appreciation while a contingent discusses the likelihood of a pullback before further parabolic moves.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as activist investor Toms Capital Investment Management recently disclosed a significant stake, fueling speculation for strategic changes to address the retailer's prolonged sales struggles. The community is split, with some viewing this as a potential catalyst for a turnaround and a deep value opportunity, while others highlight ongoing challenges with sales, management, and competition from rivals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock...

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat.com reports...

Tectonic Therapeutic (NASDAQ:TECX) Issues Earnings Results, Beats Estimates By $0.03 EPS

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of...

<ul class="summary-bullets"><li>TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.</li><li>The results expand the drug’s potential reach to a broader patient population with no approved therapies, while the Phase 2 APEX trial continues toward results in 2026.</li><li>Retail investors reacted enthusiastically on Stocktwits, calling the data “unbelievable” and “outstanding.”&nbsp;</li></ul>Shares of Tectonic Therapeutic rose about 30% in after-hours trading on Wednesday after the company reported positive topline results from a Phase 1b Part B clinical trial of TX45, its experimental Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension associated with heart failure with reduced ejection fraction.<h2 class="st-heading-2">TX45 Shows Improvements In Heart And Lung Function</h2>Tectonic said a single intravenous dose of TX45 was well tolerated, with no serious side effects or meaningful changes in blood pressure. The treatment showed clear benefits for heart and lung function by reducing pressure on the heart and lungs and improving blood flow. Key measures, such as pulmonary capillary wedge pressure, total pulmonary resistance, and mean pulmonary artery pressure, all decreased, while cardiac output increased.CEO Alise Reicin said the findings “open up the potential to expand into this additional patient population with significant unmet need and no approved therapies,” adding that the results mirrored those seen in an earlier TX45 study in heart failure with preserved ejection fraction.<h2 class="st-heading-2">Broader Development Plan</h2>The trial enrolled 14 patients and builds on earlier positive data from TX45’s Phase 1b Part A study in ejection fraction. The company is currently running the APEX Phase 2 trial to test TX45 over a 24-week treatment period in patients with ejection fraction, with topline results expected in 2026.Chief Medical Officer Marcella Ruddy said the drug showed “persistent effects at day 29” based on echocardiographic data and continued to demonstrate a favorable safety profile.<h2 class="st-heading-2">Stocktwits Users Cheer Tectonic’s TX45 Results</h2>On Stocktwits, retail sentiment for Tectonic Therapeutic was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the TX45 results as “unbelievable,” predicting the stock could reach $50.&nbsp;<stembedurl>https://stocktwits.com/paddypablo/message/634229088</stembedurl>Another user said the data looked “outstanding,” adding to their position below $22 and expecting the shares to climb further.<stembedurl>https://stocktwits.com/Gurujoe/message/634224719</stembedurl><a href="https://stocktwits.com/symbol/TECX">Tectonic’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tectonic’s stock (TECX) has declined 60% so far in 2025. (Photo credit: Getty Images)

Why Tectonic Therapeutic Stock Soared 30% After-Hours Today

TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.

Equity

Shares of Tectonic Therapeutic (TECX) soared about 6% in Wednesday’s pre-market after Oppenheimer initiated coverage of the company with an ‘Outperform’ rating.Oppenheimer has an $80 price target on Tectonic, representing an upside of over 380% from the stock’s closing price on Tuesday. The firm stated that it likes the prospects of Tectonic's lead asset, TX45, for addressing prevalent and progressive cardiovascular disorders that are currently inadequately treated.The analyst is optimistic ahead of next year's mid-stage study data readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way for a multi-billion-dollar global sales opportunity, according to TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TECX">Tectonic</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_7_02_32_AM_png_aa449b866b.webp" alt="TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>Tectonic shares closed down 35% on Tuesday following Eli Lilly's (LLY) data presentation and publication from its failed study in heart failure patients with preserved ejection fraction using a recombinant long-acting relaxin mimetic, Volenrelaxin. Tectonic’s lead candidate also seeks to treat similar cardiovascular disorders.According to Truist analyst Danielle Brill, the negative news "represents another hit to the emerging relaxin class of drugs." Still, the firm also notes that read-through should be limited as the population enrolled in Lilly's trial is distinct from those enrolled in Tectonic's.The firm, which believes Tectonic's approach to targeting Combined Post- and Pre-Capillary Pulmonary Hypertension has "the strongest rationale" and calls the selloff "overdone," maintained a ‘Buy’ rating and a $64 price target on Tectonic shares.TECX stock is down by 64% this year and by about 13% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cybersecurity-vendor-zscaler-s-stock-rises-premarket-what-s-fueling-upside/chwTMR0Rd89">Cybersecurity Vendor Zscaler’s Stock Rises Premarket: What’s Fueling The Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate

Oppenheimer stated that it likes the prospects of Tectonic's lead asset, TX45, to address prevalent and progressive cardiovascular disorders that are inadequately treated.

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Current Price	$21.23
Prev Close	$21.80
Open	$21.55
Dividend Yield	0.00%
50-Day Moving Average	$18.98
Beta	1.39
Avg. Volume	447,205.84
PE Ratio	-5.66

52-Week High	$61.07
52-Week Low	$13.70
Market Capitalization	$408.01M
EPS (Annual)	-$6.83
Price to Book	1.44
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TECX
Tectonic Therapeutic Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TECX News

TECXTectonic Therapeutic Inc.